Alzheimer's research sheds light on medication side effects


Thursday, 15 December, 2022

Alzheimer's research sheds light on medication side effects

A new study led by Western Sydney University has shed light on the treatment of Alzheimer’s disease, after researchers identified proteins causing neuronal allergy in neurons treated with Alzheimer therapeutic antibodies.

The study provides a molecular explanation of the incidence of Amyloid-Related Imaging Abnormalities (ARIA), side effects known to occur in 41% of Alzheimer’s patients undergoing treatment.

The study, conducted in stem cells and primary neurons derived from healthy non-demented donors, identified proteins causing neuronal allergy.

The lead researcher, Associate Professor Mourad Tayebi, Head of the Neuroimmunology Laboratory at Western Sydney University’s School of Medicine, said the study will guide researchers to develop and repurpose anti-allergy molecules in current Alzheimer’s medication.

“Our study shows that antibodies targeting Amyloid Beta activates a large number of allergy-related proteins in neurons which could be, in theory, effectively ‘turned off’ by using newly developed and repurposed anti-allergy molecules,” Tayebi said.

“The reason why antibody therapy causes ARIA in some patients has remained largely unknown until now. We have discovered a large proportion of the activated proteins were cell signalling proteins involved in type-1 hypersensitivity response, providing a comprehensive molecular explanation,” he said.

The study’s co-author, Professor Sir John Hardy, Institute of Neurology and Department of Molecular Neuroscience at University College London said the research had real potential to develop ways to prevent and alleviate the side effects of current antibody therapy, with follow-up studies to come.

“Our work provides a better understanding on how Anti-Amyloid Beta antibodies cause side effects in patients who already suffer from a devastating brain disorder already affecting their quality of life,” Hardy said.

Patients and their families must speak to a GP for medical advice specific to individual medical treatment plans, and always follow medical instructions for any medication prescribed by a doctor or registered healthcare professional.

Image credit: iStockphoto.com/ipopba

Related News

SA dementia-friendly action plan to roll out

An action plan will be implemented in South Australia that will see the state become more...

Dementia Australia celebrates 25 years

A new report has been released by Dementia Australia, marking 25 years in research support and...

Memory test and blood sample: early Alzheimer's diagnostics?

A new study at the University of Gothenburg is testing the potential for a digital memory test...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd